Evolving therapeutic role of bisphosphonates in multiple myeloma
2005
The Role of Bisphosphonates in Treating Multiple Myeloma
publication
Evidence: moderate
Author Information
Author(s): Ural A U, Avcu F
Primary Institution: Gulhane Military Medical Academy
Hypothesis
Can bisphosphonates have antitumor effects in multiple myeloma treatment?
Conclusion
Bisphosphonates, particularly zoledronic acid, may enhance the effectiveness of other treatments for multiple myeloma and reduce tumor burden.
Supporting Evidence
- Zoledronic acid has been shown to induce apoptosis in multiple myeloma cell lines.
- Clinical studies suggest that bisphosphonates may reduce tumor burden in patients with multiple myeloma.
- Zoledronic acid treatment has been associated with increased disease-free survival in animal models.
Takeaway
Bisphosphonates are medicines that can help treat bone problems in cancer, and they might also help fight cancer itself.
Methodology
The study involved in vitro experiments and animal models to assess the effects of zoledronic acid on multiple myeloma cells.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website